Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/hem3.70013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities Milad Rasouli Selina Troester Florian Grebien Bianca F. Goemans C. Michel Zwaan Olaf Heidenreich HemaSphere AbstractAcute myeloid leukemia (AML) is an aggressive hematological malignancy with a heterogeneous molecular landscape. In the pediatric context, the NUP98 gene is a frequent target of chromosomal rearrangements that are linked to poor prognosis and unfavorable treatment outcomes in different AML subtypes. The translocations fuse NUP98 to a diverse array of partner genes, resulting in fusion proteins with novel functions. NUP98 fusion oncoproteins induce aberrant biomolecular condensation, abnormal gene expression programs, and re‐wired protein interactions which ultimately cause alterations in the cell cycle and changes in cellular structures, all of which contribute to leukemia development. The extent of these effects is steered by the functional domains of the fusion partners and the influence of concomitant somatic mutations. In this review, we discuss the complex characteristics of NUP98 fusion proteins and potential novel therapeutic approaches for NUP98 fusion‐driven AML. 10.1002/hem3.70013 http://creativecommons.org/licenses/by/4.0/